Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort

BMC Pregnancy and Childbirth

Volumn 13, Issue , 2013, Pages

  Villa, Pia M ^a   Hämäläinen, Esa ^b   Mäki, Annukka ^b   Räikkönen, Katri ^a   Pesonen, Anu Katriina ^a   Taipale, Pekka ^c,d   Kajantie, Eero ^e,f   Laivuori, Hannele ^a,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Yla Savon terveydenhuollon kuntayhtyma   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Placental growth factor; Prediction; Preeclampsia; Soluble fms like tyrosine kinase 1; Vasoactive agents

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANT WOMAN; PROTEIN BLOOD LEVEL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84877275913     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-13-110     Document Type: Article

References (30)

1. Roberts JM. Preeclampsia: Is there value in assessing before clinically evident disease?. Obstet Gynecol 2001, 98:596-599.
2. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594. 10.1126/science.1111726, 15947178.
3. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011, 123:2856-2869. 10.1161/CIRCULATIONAHA.109.853127, 3148781, 21690502.
4. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Liberman TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658. 151901, 12618519.
5. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004, 95:884-891. 10.1161/01.RES.0000147365.86159.f5, 15472115.
6. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005. 10.1056/NEJMoa055352, 16957146.
7. Muttukrisna S, Swer M, Suri S, Jamil A, Calleja-Agius J, Gangooly S, Ludlow H, Jurkovic D, Jauniaux E. Soluble Flt-1 and PlGF: New markers of early pregnancy loss?. PLoS One 2011, 6(3):e18041. 10.1371/journal.pone.0018041, 3063178, 21448460.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683. 10.1056/NEJMoa031884, 14764923.
9. Palm M, Basu S, Larsson A, Wernroth L, Akerud H, Axelsson O. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet Gynecol Scand 2011, 90:1244-1251. 10.1111/j.1600-0412.2011.01186.x, 21568945.
10. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008, 21:9-23. 10.1080/14767050701830480, 2587364, 18175241.
11. Villa PM, Kajantie E, Räikkönen K, Pesonen A-K, Hämäläinen E, Vainio M, Taipale P, Laivuori H. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 2013, 120:64-74. 10.1111/j.1471-0528.2012.03493.x, 23126307.
12. Roberge S, Villa P, Nicolaides K, Giguere Y, VAinio M, Bakthi A, Ebrashy A, Bujold E. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012, 31:141-146. 10.1159/000336662, 22441437.
13. Pihkala J, Hakala T, Voutilainen P, Raivio K. [Characteristic of recent fetal growth curves in finland]. Duodecim 1989, 105:1540-1546.
14. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005, 192:734-741. 10.1016/j.ajog.2004.12.052, 15746665.
15. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007, 197:244-e1-244.e8.
16. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011, 24:1187-1207. 10.3109/14767058.2011.589932, 3384532, 21827221.
17. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012, 206:58.e1-58.e8.
18. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadjani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012, 125:911-919. 10.1161/CIRCULATIONAHA.111.054361, 3319742, 22261192.
19. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89:770-775. 10.1210/jc.2003-031244, 14764795.
20. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53:812-818. 10.1161/HYPERTENSIONAHA.108.127977, 19273739.
21. Wa Law L, Sahota DS, Chan LW, Chen M, Lau TK, Leung TY. Serum placental growth factor and fms-like tyrosine kinase 1 during first trimester in chinese women with pre-eclampsia-a case-control study. J Matern Fetal Neonatal Med 2011, 24:808-811. 10.3109/14767058.2010.531309, 21534854.
22. Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32:732-739. 10.1002/uog.6244, 18956425.
23. Cowans NJ, Stamatopoulou A, Matwejew E, von Kaisenberg CS, Spencer K. First-trimester placental growth factor as a marker for hypertensive disorders and SGA. Prenat Diagn 2010, 30:565-570.
24. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010, 122:478-487. 10.1161/CIRCULATIONAHA.109.895458, 20644016.
25. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004, 50:1702-1703. 10.1373/clinchem.2004.036715, 15331514.
26. Polliotti BM, Fry A, Gordon Saller DN, Jr Mooney RA, Cox CM, Richard K. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003, 101:1266-1274. 10.1016/S0029-7844(03)00338-7, 12798535.
27. Wathen K, Tuutti E, Stenman U, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006, 91:180-184. 10.1210/jc.2005-1076, 16263826.
28. Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand 2010, 89:143-146. 10.3109/00016340903289892, 20021269.
29. Vatten LJ, Eskild AN, Tom IL, Jeansson SJ, Pal A, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007, 196:239e1-239e6.
30. Oudejans CB, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA. Genetics of preeclampsia: Paradigm shifts. Hum Genet 2007, 120:607-612.